Browse articles from EyeWorld.org related to MIGS. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
This article recapped a session that ASCRS co-sponsored at the 2021 virtual meeting of the American Glaucoma Society (AGS), which covered topics relating to patients with controlled glaucoma but visually significant cataracts.
➤ Full results from Phase 3 study for presbyopia-correcting eye drop ➤ Cells from two donors treat dozens of patients with corneal endothelial disease ➤ Study: Dry eye treatment reduces halos after cataract surgery ➤ NDA accepted for IND application for novel, investigational dry eye drug ➤ Acquisition of ophthalmic drug candidate ➤ ASCRS events
➤ FDA grants IDE for MIGS device to start pivotal trial ➤ Breakthrough therapy designation granted for possible Stargardt treatment ➤ Refractive surgery uptick continues ➤ First patient dosed in trial for light-activated optogenetic monotherapy for RP ➤ Diagnostic device company acquires ophthalmic device manufacturer ➤ Two ophthalmic companies partner ➤ ASCRS news and events
Ophthalmology will see its first major live meeting since the pandemic started with the 2021 ASCRS Annual Meeting. “Just as the live meeting will be reflective of our interesting times, this issue of EyeWorld is a product of our unique year, covering many topics that will help the modern ophthalmologist and glaucoma specialist succeed,” said Nathan Radcliffe, MD, Glaucoma editor.
Some MIGS options are approved only in conjunction with cataract surgery, while others are not limited in this way. Three ophthalmologists EyeWorld spoke with think there is a value in uncoupling some MIGS procedures from cataract surgery, yet two of the three do not perform off-label standalone MIGS.
Infection is a risk for any ocular surgery, but there are a few reasons why there isn’t a lot of discussion about infection when it comes to glaucoma procedures. MIGS, which have become increasingly common, have a lower infection risk profile compared to incisional glaucoma surgery.
➤ FDA grants De Novo authorization for new intense pulsed light device ➤ Post-approval study requirements fulfilled for clear corneal incision sealant ➤ Interim analysis for acute adenoviral conjunctivitis drug ➤ NDA resubmission for injection to treat macular edema associated with uveitis ➤ FDA approves abbreviated NDA for glaucoma drug ➤ Study: Functional and psychosocial impact of Demodex blepharitis ➤ Next ASCRS Journal Club on May 13
➤ Researchers develop living 3D lab model of human retina ➤ Real-world data shows home AMD monitoring program is better than standard of care ➤ FDA approves new ophthalmic viscosurgical device ➤ Positive topline data for photobiomodulation for dry AMD ➤ Positive topline data for bevacizumab-vikg for retinal indications
➤ FDA approves elements of artificial vision system for blind patients ➤ Expanded indication for MIGS device ➤ 5-year pivotal trial data for MIGS device ➤ Topline results from Phase 2 study of investigational MGD treatment
➤ FDA accepts NDA for fixed-combination mydriatic agent ➤ NDA accepted by FDA for dry eye nasal spray ➤ NDA submitted for drop to treat presbyopia ➤ Study to assess outcomes of ab interno canaloplasty ➤ Largest study of glaucoma genetics published ➤ Iridex and Topcon enter into strategic agreement ➤ COVID-19 vaccine update ➤ ASCRS Journal Club on March 11